Comparison of the pharmacokinetics of MR-107A-02, a novel fast-absorbing formulation of meloxicam, versus standard meloxicam reference: a phase I study
MR-107A-02 demonstrated more rapid absorption than reference, as evidenced by a higher C<sub>max</sub>, and shorter T<sub>max</sub> values. These findings highlight the potential utility of oral MR-107A-02's fast-release design in an acute pain setting.
Authors
- Arun Kumar Jaiswal (ORCID: https://orcid.org/0000-0002-0558-483X)
- Andrew A. Shaw (ORCID: https://orcid.org/0000-0002-7241-3213)
- Mark Shiyao Liu
- Todd Bertoch (ORCID: https://orcid.org/0000-0001-9896-5238)
- Jeffrey Smith (ORCID: https://orcid.org/0000-0003-3827-4851)
- Matthew A. Hummel
Institutions
- Cenex (United Kingdom) (GB)
- Tris Pharma (United States) (US)
Publication Details
- Journal
- Expert Opinion on Drug Delivery
- Published
- 2025-09-16
- DOI
- https://doi.org/10.1080/17425247.2025.2561710
- Primary Topic
- Analytical Methods in Pharmaceuticals
- Type
- article
- Field-Weighted Citation Impact
- 0.00